/
Oncology
Locally Advanced or Metastatic Breast Cancer
9
Pipeline Programs↗
7
Active Trials↗
6
Companies Involved↗
Locally Advanced or Metastatic Breast Cancer is an early-stage landscape with 9 programs across 6 companies. The most active players are Roche, Jiangsu Simcere Pharmaceutical Co., Ltd., MediLink Therapeutics (Suzhou) Co., Ltd.. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 37
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
8 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
7
clinical trials
Active, not recruiting4 · 57%
Recruiting2 · 29%
Not yet recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)